The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus

Kauppila, Saila; Kotila, Vesa; Knuuti, Eila; Väre, Päivi O.; Vittaniemi, Pia; Nissi, Ritva

doi:10.1016/j.ajog.2009.09.030

Cited by 18 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 As with the current study, posttreatment histologic examination showed decreased inflammatory lymphoid infiltrate. 14 Potential limitations of this study include a relatively small sample size, although a statistically significant difference was found between the treatment groups. The sample size was calculated based on prior efficacy studies of other medications used for the treatment of LS.…”

Section: Discussionmentioning

confidence: 86%

A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus

Goldstein

Creasey

Pfau

et al. 2011

Journal of the American Academy of Dermatology

121

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus

Goldstein

Creasey

Pfau

et al. 2011

Journal of the American Academy of Dermatology

121

View full text Add to dashboard Cite

“…The purpose of this study was to assess female sexual function in women with LS at baseline and after treatment utilizing clobetasol, an ultrapotent corticosteroid (the gold standard treatment) vs. pimecrolimus, a topical calcineurin inhibitor. Pimecrolimus has been shown in non‐randomized trials to be an effective treatment for LS, but has never been compared to clobetasol in a clinical trial [11].…”

Section: Introductionmentioning

confidence: 99%

The Treatment of Vulvar Lichen Sclerosus and Female Sexual Dysfunction

Burrows

Creasey

Goldstein

2011

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction Women with lichen sclerosus (LS) are more likely to have dyspareunia, decreased orgasm, and decreased coital frequency as compared to unaffected women. It is unknown whether standard medical therapy to treat LS results in improved sexual functioning. Aims To describe sexual function in women with LS and to assess if LS-associated sexual dysfunction decreases after appropriate medical therapy. Methods Women enrolled in a double-blind trial 12-week trial comparing clobetasol vs. pimecrolimus for the treatment of LS were administered the Female Sexual Distress Scale (FSDS) upon enrollment and at the end of the trial. The difference in the total score on the FSDS between the two groups before and after treatment was assessed with a paired t-test. Main Outcome Measures The change in mean FSDS score from baseline to 12 weeks. Results A total of 31 out of 36 enrolled women had adequate treatment of LS as determined by a dermatopathologist’s evaluation of pre and post-treatment biopsy specimens. The mean baseline FSDS score for the clobetasol group was 29 and, post-treatment, it was 15 (P = 0.001). In the pimecrolimus group, the mean baseline FSDS score was 27 and, post–treatment, it was 21 (P = 0.001). Conclusions Despite adequate treatment, women with LS continue to have significant sexual dysfunction as assessed by the FSDS.

show abstract

“…Also the number of CD57-negative natural killer cells was decreased. Pimecrolimus did not affect B cells [11].…”

Section: Pimecrolimusmentioning

confidence: 77%

“…In the pimecrolimus group, blood concentrations of pimecrolimus were above the threshold of detection and higher than those detected after use on skin; the mean value on day 14 was 2.32 ng/ml (0.6-10), that on day 28 was 2.84 ng/ml (0. [6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The mean quantity of pimecrolimus cream used during the month of treatment was 34 g. Blood levels of pimecrolimus when treating psoriasis with oral pimecrolimus were above 50 ng/ml.…”

Section: Oral Lichen Planusmentioning

confidence: 96%

Anti-Inflammatory Treatment

Fistarol¹,

Itin²

2011

Topical Applications and the Mucosa

View full text Add to dashboard Cite

Inflammatory mucosal disorders are treated conventionally with potent or superpotent topical corticosteroids. For more than 20 years, topical cyclosporine has been used in the management of oral mucous membrane affections. Recently other topically applied calcineurin inhibitors, namely tacrolimus and pimecrolimus, expanded the armamentarium for the treatment of inflammatory mucosal diseases. This chapter places its main emphasis on the efficacy and safety of topical calcineurin inhibitors in the management of different oral and genital conditions, including anogenital lichen sclerosus (LS), oral and genital lichen planus, plasma cell balanitis and vulvitis, mucous membrane pemphigoid and pemphigus vulgaris, all conditions having usually a protracted course, requiring long-lasting treatment. There is current evidence for the effectiveness of both pimecrolimus and tacrolimus in the topical treatment of inflammatory oral mucosal diseases and genital dermatoses, especially oral lichen planus and genital LS.

show abstract

The effect of topical pimecrolimus on inflammatory infiltrate in vulvar lichen sclerosus

Cited by 18 publications

References 5 publications

A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus

A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus

The Treatment of Vulvar Lichen Sclerosus and Female Sexual Dysfunction

Anti-Inflammatory Treatment

Contact Info

Product

Resources

About